MovDisordV3, Main, Exploration, bibRecord, 005D08

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

Identifieur interne : 005D08 ( Main/Exploration ); précédent : 005D07; suivant : 005D09

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

Auteurs : Daniele Bravi [États-Unis] ; Thomas L. Davis [États-Unis] ; M. Maral Mouradian [États-Unis] ; Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1993.

RBID : ISTEX:39A29AC2104BE6E282DF9262198464D52F45D5CA

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, EMD 49980, Homme, Parkinson maladie, Stimulant dopaminergique, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Antiparkinson agent, Brain (drug effects), Brain (physiopathology), Chemotherapy, Dopamine Agents (therapeutic use), Dopamine agonist, Double-Blind Method, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), EMD 49980, Female, Human, Humans, Indoles (therapeutic use), Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Partial dopamine agonist, Pyridines (therapeutic use), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Treatment.
MESH :
- chemical , adverse effects : Levodopa.
- chemical , drug effects : Receptors, Dopamine.
- chemical , physiology : Receptors, Dopamine.
- chemical , therapeutic use : Dopamine Agents, Indoles, Levodopa, Pyridines.
- drug effects : Brain, Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- physiopathology : Brain, Dyskinesia, Drug-Induced, Parkinson Disease.
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged.

Abstract

The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co‐administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa‐induced dyskinesias.

Url:

https://api.istex.fr/document/39A29AC2104BE6E282DF9262198464D52F45D5CA/fulltext/pdf

DOI: 10.1002/mds.870080214

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of parkinson's disease with the partial dopamine agonist EMD 49980</title>
<author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name>
</author>
<author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</author>
<author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:39A29AC2104BE6E282DF9262198464D52F45D5CA</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080214</idno>
<idno type="url">https://api.istex.fr/document/39A29AC2104BE6E282DF9262198464D52F45D5CA/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003987</idno>
<idno type="wicri:Area/Istex/Curation">003987</idno>
<idno type="wicri:Area/Istex/Checkpoint">003F75</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Bravi D:treatment:of:parkinson</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8097280</idno>
<idno type="wicri:Area/PubMed/Corpus">004C64</idno>
<idno type="wicri:Area/PubMed/Curation">004C64</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004B81</idno>
<idno type="wicri:Area/Ncbi/Merge">004871</idno>
<idno type="wicri:Area/Ncbi/Curation">004871</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004871</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Bravi D:treatment:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">008F47</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:93-0457164</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003744</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003080</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003662</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Bravi D:treatment:of:parkinson</idno>
<idno type="wicri:Area/Main/Merge">009082</idno>
<idno type="wicri:Area/Main/Curation">005D08</idno>
<idno type="wicri:Area/Main/Exploration">005D08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of parkinson's disease with the partial dopamine agonist EMD 49980</title>
<author><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="195">195</biblScope>
<biblScope unit="page" to="197">197</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">39A29AC2104BE6E282DF9262198464D52F45D5CA</idno>
<idno type="DOI">10.1002/mds.870080214</idno>
<idno type="ArticleID">MDS870080214</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson agent</term>
<term>Brain (drug effects)</term>
<term>Brain (physiopathology)</term>
<term>Chemotherapy</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Double-Blind Method</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>EMD 49980</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Partial dopamine agonist</term>
<term>Pyridines (therapeutic use)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (physiology)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Pyridines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>EMD 49980</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Stimulant dopaminergique</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co‐administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa‐induced dyskinesias.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Bravi, Daniele" sort="Bravi, Daniele" uniqKey="Bravi D" first="Daniele" last="Bravi">Daniele Bravi</name>
</region>
<name sortKey="Chase" sort="Chase" uniqKey="Chase" last="Chase">Chase</name>
<name sortKey="Davis, Thomas L" sort="Davis, Thomas L" uniqKey="Davis T" first="Thomas L." last="Davis">Thomas L. Davis</name>
<name sortKey="Mouradian, M Maral" sort="Mouradian, M Maral" uniqKey="Mouradian M" first="M. Maral" last="Mouradian">M. Maral Mouradian</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D08 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:39A29AC2104BE6E282DF9262198464D52F45D5CA
   |texte=   Treatment of parkinson's disease with the partial dopamine agonist EMD 49980
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.